Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments
105167	16/WM/0365	210358	HRA Approval	GSK UC: A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitis			Yes	11/07/2017	0	0	0	56	245	301	No		08/07/2016	13/09/2016	09/11/2016	19/10/2016	08/11/2016	Please Select...	15/11/2016	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	Very tight inclusion criteria; 13 pts pre-screened to date
105168	16/LO/1384	211114	HRA Approval	ALLURE: Safety and tolerability of secukinumab in 2mL Prefilled syringes			Yes	16/02/2017	0	0	0	37	111	148	No		01/09/2016	21/09/2016	12/10/2016	25/10/2016	28/10/2016	Please Select...	07/02/2017	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	The study was signed off in October, but there has been a long delay in delivery of IMP. Drug delivered 09/02/17.
105169	16/NW/0517	188554	HRA Approval	ACCORD: MYELOMA XII: A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT Consolidation and maintenance strategy in			Yes	26/05/2017	0	0	0	145	66	211	No		29/06/2016	27/10/2016	27/10/2016	21/03/2017	21/03/2017	Please Select...	23/03/2017	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	Originally delayed due to sponsor's negotiations with drug company. Drug became available and sponsor signed contracts.
105170	16/LO/1810	209789	HRA Approval	UNITY: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)			No		0	0	0				No		19/10/2016	25/11/2016	03/01/2017			Please Select...		FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	Capacity issues in radiology; sponsor's contracting department very slow
105171	16/LO/1822	212944	HRA Approval	VICTORIA: A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction (HFrEF) - VeriCiguaT gObal study in subjects with heart failure and Reduced ejectIon frAction			Yes	23/03/2017	0	0	0	62	101	163	No		26/04/2016	11/10/2016	07/12/2016	08/12/2016	12/12/2016	Please Select...	17/01/2017	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	Supply of IMP not delivered until mid January 2017. Member of research team on long term sick leave.
105172	17/NW/0019	212375	HRA Approval	A phase 3b/4 randomized double blind placebo controlled study of methotrexate (mtx) withdrawal in subjects with rheumatoid arthritis (ra) treated with tofacitinib 11mg modified release (mr) formulation			No		0	0	0	81			No		28/07/2016	20/03/2017	03/04/2017	10/05/2017	09/06/2017	Please Select...	07/07/2017	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	Sponsor Green light delayed due to SIV
105173	17/EE/0079	220827	HRA Approval	Avacopan in patients with Vasculitis (ANCA associated vasculitis			No		0	0	0	155			No		02/12/2017	25/01/2017	06/04/2017	13/06/2017	29/06/2017	Please Select...	01/09/2017	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	PI on annual leave until end of Aug 2017
105174	16/SC/0655	212212	HRA Approval	KReBS: Knee Replacement Bandaging Study			Yes	27/04/2017	0	0	0	7	28	35	Yes		30/11/2016	23/03/2017	08/02/2017	30/03/2017	30/03/2017	Please Select...	24/04/2017	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	
105175	16/LO/1386	199366	HRA Approval	IDDEA-HF: Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment with Elamipretide in Patients Hospitalized with Severe Congestion due to Heart Failure			No		0	0	0	152			No		09/06/2016	01/09/2016	07/11/2016	27/01/2017	31/01/2017	Please Select...	10/04/2017	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	Drugs delivered to site 06/04/2017; green light 10/04/2017
105176	17/EM/0005	215706	HRA Approval	GALACTIC-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction			Yes	11/04/2017	0	0	0	19	36	55	Yes		24/10/2016	15/02/2017	15/02/2017	28/02/2017	06/03/2017	Please Select...	29/03/2017	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	Issues with IT information governance delayed delivery of study IT devices
105177	17/SC/0142	215503	HRA Approval	The 65 Trial: Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension			Yes	13/07/2017	0	0	0	104	10	114	No		22/02/2017	21/03/2017	24/04/2017	13/06/2017	03/07/2017	Please Select...	04/07/2017	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	Sponsor green light not given until 3 weeks after SIV
105178	16/LO/2067	209688	HRA Approval	OPTIMISE II: Optimisation of Peri-operative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) Trial: Open, multi-centre, randomised controlled trial of cardiac output-guided fluid therapy with low dose inotrope infusion compared to usual care in patients undergoing major elective gastrointestinal surgery.			No		0	0	0				No		12/10/2016	15/02/2017	06/01/2017			Please Select...		TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	Trial centre is starting off sites in waves; likely to initiate late July/Aug 2017 - pending SIV date
105677	16/LO/0436	162098	Please Select...	APRICOT: Treatment of pustular psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies.			No		0	0	0				Within 70 Days		20/01/2017	27/04/2017	05/07/2016			Please Select...		FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	
105679	16/LO/2190	201357	Please Select...	PLUM: Pustular psoriasis, eLucidating Underlying Mechanisms			No		0	0	0				Within 70 Days		03/04/2017	27/04/2017	07/03/2017			Please Select...		FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	
105680	16/EM/0384	182787	Please Select...	BMS AUGUSTUS: An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention			No		0	0	0				Within 70 Days		13/06/2017	16/06/2017	21/11/2016			Please Select...		FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	